# US 2026/0216171 A1 · Pharmaceutical solution for oral dosage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216171 A1
- Document ID: US20260216171A1
- Status: Published application
- Kind: A1
- Application number: 19/434,304
- Filed: 2025-12-29
- Published: 2026-07-30
- Earliest claimed: 2018-08-18
- Assignees: Liqmeds Worldwide Limited
- Applicants: Liqmeds Worldwide Limited
- Inventors: Sandip MEHTA; Manish Kumar UMRETHIA; Jayanta MANDAL
- Web page: https://patentgrep.com/patent/US20260216171A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A liquid pharmaceutical composition consisting of:
a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, wherein the vigabatrin is present in the composition in the range of about 1 mg/mL to about 250 mg/mL;
a preservative;
a buffering agent;
a sweetener;
at least one of a flavoring agent, a solubilizer, a co-solvent, an antioxidant, a surfactant, an antifoaming agent, a chelating agent, a suspending agent, a viscosity builder, and a coloring agent; and
quantum sufficit (q.s.) water;
wherein the liquid pharmaceutical composition is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%; wherein the total impurities are defined as the sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months.

### Claim 11 (depends on 10)

The liquid pharmaceutical composition of claim 10, wherein the vigabatrin is present in an amount from about 50 mg/mL to about 150 mg/mL in the composition.

### Claim 12 (depends on 10)

The liquid pharmaceutical composition of claim 10, wherein the flavoring agent is present in an amount from about 0.001 wt % to about 5 wt % and is selected from the group consisting of: vanilla, lemon, orange, grape, lime, grapefruit, apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, strawberry, tutti-fruity flavor, mint flavor, and combinations thereof.

### Claim 13

A liquid pharmaceutical composition comprising:
a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, at about 1 mg/mL to about 250 mg/mL;
a preservative in a range of about 0.001 wt % to about 1 wt %;
a sweetener in a range of about 0.05 wt % to about 40 wt %; and
quantum sufficit (q.s.) water;
wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%, and
wherein the total impurities are defined as a sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months,
with the proviso that the liquid pharmaceutical composition does not comprise any active pharmaceutical ingredient other than vigabatrin.

### Claim 14 (depends on 13)

The liquid pharmaceutical composition of claim 13, comprising from about 0.001 wt % to about 5 wt % of a flavoring agent.

### Claim 15 (depends on 14)

The liquid pharmaceutical composition of claim 14, wherein the flavoring agent is selected from vanilla, lemon, orange, grape, lime, grapefruit, apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, strawberry, tutti-fruity flavor, mint flavor, and combinations thereof.

### Claim 16 (depends on 13)

The liquid pharmaceutical composition of claim 13, comprising a buffering agent.

### Claim 17 (depends on 16)

The liquid pharmaceutical composition of claim 16, wherein buffering agent is selected from acetic acid, adipic acid, ammonium carbonate, ammonium hydroxide, ammonium phosphate, boric acid, citric acid, diethanolamine, fumaric acid, hydrochloric acid, lactic acid, malic acid, nitric acid, propionic acid, potassium acetate, potassium bicarbonate, potassium chloride, potassium citrate, potassium metaphosphate, potassium phosphate, sodium acetate, sodium bicarbonate, sodium borate, sodium carbonate, sodium chloride, sodium. citrate, sodium glycolate, sodium hydroxide, sodium lactate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium propionate, succinic acid, sulfuric acid, tartaric acid, triethylamine, triethanolamine, tromethamine, trolamine, and salts thereof, and any combinations thereof.

### Claim 18 (depends on 13)

The liquid pharmaceutical composition of claim 13, wherein the sweetener is present in an amount from about 0.01 wt % to about 10 wt % and is selected from glucose, sucralose, maltitol, trehalose, fructose, xylose, dextrose, galactose, tagatose, maltose, sucrose, glycerol, dulcitol, mannitol, lactitol, sorbitol, xylitol, saccharine or the corresponding sodium, potassium, or calcium salt, cyclamate or the corresponding sodium or calcium salt, aspartame, acesulfame or the potassium salt thereof, dulcin, ammonium glycyrrhizinate, alitame, inulin, isomalt, neohesperidin dihydrochalcone, thaumatin, and combinations thereof.

### Claim 19 (depends on 13)

The liquid pharmaceutical composition of claim 13, wherein the preservative is selected from benzyl alcohol, chloro-butanol, chloro-cresol, alkyl esters of parabens, phenol, phenyl ethanol, benzoic acid, potassium sorbate, sodium benzoate, propylene glycol, chloroform, and combinations thereof.

### Claim 20

A liquid pharmaceutical composition comprising:
a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, at about 1 mg/mL to about 250 mg/mL;
a preservative in a range of about 0.001 wt % to about 1 wt %;
one or more excipients in a range of about 0.001 wt % to about 50 wt % and selected from:
a sweetening agent, a flavoring agent, a buffering agent, a solubilizer, a co-solvent, an antioxidant, a surfactant, an antifoaming agent, a chelating agent, a suspending agent, a viscosity builder, and a coloring agent; and
quantum sufficit (q.s.) water;
wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%, and
wherein the total impurities are defined as a sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months,
with the proviso that the liquid pharmaceutical composition does not comprise any active pharmaceutical ingredient other than vigabatrin.

### Claim 21 (depends on 20)

The liquid pharmaceutical composition of claim 20, comprising from about 0.001 wt % to about 5 wt % of a flavoring agent.

### Claim 22 (depends on 21)

The liquid pharmaceutical composition of claim 21, wherein the flavoring agent is selected from the group consisting of: vanilla, lemon, orange, grape, lime, grapefruit, apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot, strawberry, tutti-fruity flavor, mint flavor, and combinations thereof.

### Claim 23 (depends on 20)

The liquid pharmaceutical composition of claim 20, comprising a buffering agent.

### Claim 24 (depends on 23)

The liquid pharmaceutical composition of claim 23, wherein buffering agent is selected from acetic acid, adipic acid, ammonium carbonate, ammonium hydroxide, ammonium phosphate, boric acid, citric acid, diethanolamine, fumaric acid, hydrochloric acid, lactic acid, malic acid, nitric acid, propionic acid, potassium acetate, potassium bicarbonate, potassium chloride, potassium citrate, potassium metaphosphate, potassium phosphate, sodium acetate, sodium bicarbonate, sodium borate, sodium carbonate, sodium chloride, sodium. citrate, sodium glycolate, sodium hydroxide, sodium lactate, sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium propionate, succinic acid, sulfuric acid, tartaric acid, triethylamine, triethanolamine, tromethamine, trolamine, and salts thereof, and any combinations thereof.

### Claim 25 (depends on 20)

The liquid pharmaceutical composition of claim 20, comprising from about 0.01 wt % to about 10 wt % of a sweetening agent.

### Claim 26 (depends on 25)

The liquid pharmaceutical composition of claim 25, wherein the sweetening agent is selected from glucose, sucralose, maltitol, trehalose, fructose, xylose, dextrose, galactose, tagatose, maltose, sucrose, glycerol, dulcitol, mannitol, lactitol, sorbitol, xylitol, saccharine or the corresponding sodium, potassium, or calcium salt, cyclamate or the corresponding sodium or calcium salt, aspartame, acesulfame or the potassium salt thereof, dulcin, ammonium glycyrrhizinate, alitame, inulin, isomalt, neohesperidin dihydrochalcone, thaumatin, and combinations thereof.

### Claim 27 (depends on 20)

The liquid pharmaceutical composition of claim 20, comprising an antioxidant selected from butylatedhydroxyanisole (BHA), butylatedhydroxy toluene (BHT), sodium metabisulfite, ascorbic acid, alphatocopherol, sodium edetate and combination thereof.

### Claim 28 (depends on 20)

The liquid pharmaceutical composition of claim 20, wherein the preservative is selected from benzyl alcohol, chloro-butanol, chloro-cresol, alkyl esters of parabens, phenol, phenyl ethanol, benzoic acid, potassium sorbate, sodium benzoate, propylene glycol, chloroform, and combinations thereof.
